Analysis of immunizations against Human Virus Papilloma (HPV) in the state of Piauí
DOI:
https://doi.org/10.33448/rsd-v9i7.4715Keywords:
Immunization; Vaccine; HPV.Abstract
Human Papilloma Virus (HPV) is a virus with DNA capable of causing lesions on the skin and mucous membranes, which can cause warts or precursor lesions of cancer that can be classified as low and high oncogenic risk. The present study aimed to quantify and analyze the immunizations against HPV carried out in the state of Piauí. It was a documentary, retrospective, descriptive research with a quantitative approach. Data were collected from the Information System of the National Immunization Program (SI-PNI) through the doses applied, extracting the year, sex, age group and the number of doses of immunizations. Between 2014-2019, 482,763 doses of the quadrivalent vaccine were administered. Analyzing immunizations by year of administration, the following percentage distribution was obtained: 2014 (27%), 2015 (18%), 2016 (7%), 2017 (20%), 2018 (15%) and 2019 (13%). The vaccine administration in females (75%) was considerably higher than in males (25%). Individuals aged 11 years (24%) and 14 years (7%) are those who received the most and least, respectively, the vaccine doses. Regarding the doses required for prevention, there was a decrease in the percentage of doses applied, being distributed in the following frequency: 1st dose (58%), 2nd dose (41%) and 3rd dose (1%). The research made it possible to know the profile of immunizations against HPV in the state of Piauí. It is necessary to implement educational actions on HPV with the respective active search of individuals with incomplete schemes to achieve the goal of vaccination coverage.
References
Alves, A. C.; Fratucci, A.S.; Silveira, A. C. Z.; Santoro, G. M.; Rezende, L. F. (2017). Notícias veiculadas na mídia a respeito de meninas com reação após a vacina contra o HPV. Unimontes Científica, 19(1), 114-121.
Brasil (2014). Guia prático sobre o HPV: Guia de perguntas e respostas para profissional da saúde. Recuperado de: <https://portalarquivos2.saude.gov.br/images/pdf/2014/marco/07/guia-perguntas-repostas-MS-HPV-profissionais-saude2.pdf>.
Brasil (2014). Informe técnico sobre a Vacina Papilomavírus Humano (HPV) na atenção básica. Recuperado de: <https://saude.es.gov.br/Media/sesa/PEI/Informe_Tecnico_Introducao_vacina_HPV_2014.pdf>.
Brasil (2017). Guia Prático sobre HPV: Perguntas e respostas. Recuperado de: http://portalarquivos2.saude.gov.br/images/pdf/2017/dezembro/07/Perguntas-e-respostas-HPV-.pdf.
Brasil (2018). Informe técnico da ampliação da oferta das vacinas papilomavírus humano 6, 11, 16 e 18 (recombinante) – vacina HPV quadrivalente e meningocócica C (conjugada). Recuperado de: < https://www.saude.gov.br/images/pdf/2018/marco/14/Informe-T--cnico-HPV-MENINGITE.pdf>.
Chow, L.T.; Broker, T.R. (2013). Human papillomavirus infections: warts or cancer? Cold Spring Harbor perspectives in biology, 5 (7), 1-17.
Daudt, C.; Silva, F. R. C.; Streck, A. F.; Weber, M. N.; Mayer, F. Q.; Cibulsk, S. P.; Canal, C.W. (2016). How many papillomavirus species can go undetecdet in papilloma lesions? Scientific Reports, 6, 36480. https://doi.org/10.1038/srep36480.
Egawa, N.; Doorbar, J. The low-risk papillomaviruses. Elsevier, 231 (1), 119-127. https://doi.org/10.1016/j.virusres.2016.12.017.
Farias, C.C.; Jesus, D. V.; Moraes, H. S.; Buttenbender, I. F.; Martins, I. S.; Souto, M. G.; Filho, P. H. B. H. G.; Costa, R. M.; Silva, S. O.; Ferreira, T. S. I.; Coutinho, V. V. S.; Minotto, H. R. T.; Fonseca, A. J. (2016). Factors related to non-compliance to HPV vaccination in Roraima - Brazil: A region with a high incidence of cervical cancer. BMC Health Services Research. 16 (1), 417. https://doi.org/10.1186/s12913-016-1677-y.
GARCIA, MARCELO. (2017) Discursos alternativos sobre a vacinação contra o hpv: análise das mensagens em uma comunidade virtual no facebook. Cadernos do Tempo Presente, (27), 101-111. https://doi.org/10.33662/ctp.v0i27.7488.
Glenn, W. K., Whitaker, N. J.; Lawson, J. S. (2012). High risk human papillomavirus and Epstein Barr virus in human breast milk. BMC research notes, 5(1), 477. https://doi.org/10.1186/1756-0500-5-477.
Graham, S. V. (2017). The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond), 131 (17): 2201–2221. https://doi.org/10.1042/CS20160786.
Ibrahim, A.; Robadi, M. P.; Ducatman, B. S. The Importance of High-Risk Human Papillomavirus Types Other Than 16 and 18 in Cervical Neoplasia. Archives of Pathology & Laboratory Medicine, 142 (6), 693-695. https://doi.org/10.5858/arpa.2017-0563-RA.
Instituto Nacional de Câncer (2012). Perguntas frequentes: HPV. Recuperado de: < https://www.inca.gov.br/perguntas-frequentes/hpv>.
Instituto Nacional de Câncer (2017). Estimativa 2018: incidência de câncer no Brasil. Recuperado de: http://www1.inca.gov.br/rbc/n_64/v01/pdf/15-resenha-estimativa-2018-incidencia-de-cancer-no-brasil.pdf.
Rodrigues, A.N.; Bukowski, A.; Paulino, E.; Louis, J.St.; Barrichello, A.; STERNBERG, C.; GIFONI, M. A. C.; LUCIANI, S.; GOSS, P. E. An alert to Latin America: Current human papillomavirus vaccination trends highlight key barriers to successful implementation. Cancer, 123 (12), 2193-2199. https://doi.org/10.1002/cncr.30647.
Trottier, H.; Mayrand, H.; Coutlee, F.; Monnier, P.; Laporte, L.; Niybizi, J.; Carceller, A.M.; Fraser, W.D.; Brassard, P.; Lacroix, J.; Francoeur, D.; Bédard, M.J.; Girard, I.; Audibert, F.. Human papillomavirus (HPV) perinatal transmission and risk of HPV persistence among children: Design, methods and preliminary results of the HERITAGE study. Papillomavirus Research, 2, 145-152. http://dx.doi.org/10.1016/j.pvr.2016.07.001.
Zardo, G.P.; Farah, F. P.; Mendes, F. G.; Franco, C. A. G. S.; Molina, G. V. M.; Melo, G. N.; Kusma, S. Z. (2014). Vacina como agente de imunização contra o HPV. Ciência & Saúde Coletiva, 19(9), 3799-3808. https://doi.org/10.1590/1413-81232014199.01532013.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.